ArticleMolecular biology reports2026
Endothelial dysfunction in aging associated with reduced Niban phosphorylation.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCardiovascular diseases are the leading cause of mortality worldwide, with aging and endothelial dysfunction being key contributors to its progression. Age-related vascular dysfunction is characterized by impaired endothelial-dependent relaxation, increased vascular inflammation, and heightened susceptibility to injury, all of which exacerbate cardiovascular risk. The multi-functional protein Niban restores vascular function following injury, with reduced Niban phosphorylation linked to activation of mitogen-activated protein kinase (MAPK) pathways. We hypothesized that reduced Niban phosphorylation and increased inflammatory MAPK signaling would be associated with vascular dysfunction in aging that can be attenuated by NiPp, a cell permeant phosphomimetic peptide of Niban. METHODS AND
resultsAortas from young (3-months-old, N = 8) and aged (20- to 23-month-old N = 8) rats were assessed for vascular reactivity as well as protein levels and protein phosphorylation. Aged aortas displayed impaired contractility, endothelial-dependent relaxation, reduced phosphorylated Niban levels, and increased phosphorylation of inflammatory MAPK pathway elements including c-Jun N-terminal kinase, MAP kinase-activated protein kinase 2, phosphorylated cAMP response element-binding protein, and downstream vascular cell adhesion molecule-1. Aged aortas also exhibited greater IL-1β-induced loss of endothelial-dependent relaxation ex vivo, which was attenuated by NiPp treatment.
conclusionThese results identify reduced Niban phosphorylation and increased MAPK signaling as contributors to age-related endothelial dysfunction and highlight Niban phosphorylation as a possible target for treating vascular aging and associated cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.